361 Capital’s Surmodics SRDX Stock Holding History

361 Capital’s Portfolio SRDX Stock Details SRDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-23,381	Closed	-$1.75M	–	403
2018 Q3	$1.75M	Buy	+23,381	New	+$1.61M	0.38%	115

Other funds holding SRDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Trigran Investments Northbrook, Illinois $545M AUM 56.2% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

361 Capital's SRDX Position: Q4 2018 in Review

361 Capital sold out of Surmodics (SRDX) in Q4 2018, closing a stake of 23,381 shares — an estimated $1.75M sold.

361 Capital first reported a position in SRDX in Q3 2018 and held it in 1 quarter. The position peaked at $1.75M in Q3 2018. 161 funds tracked by Wall St. Rank hold SRDX as of Q4 2018.

361 Capital reported no remaining Surmodics position as of Q4 2018 after selling out during the quarter.
361 Capital sold 23,381 Surmodics shares in Q4 2018, an estimated $1.75M.
361 Capital first reported a position in Surmodics in Q3 2018 and held it in 1 quarter.
361 Capital's Surmodics position peaked at $1.75M in Q3 2018.
161 funds tracked by Wall St. Rank held Surmodics as of Q4 2018.

Based on 361 Capital's 13F filing for Q4 2018, filed 8 Feb 2019.